Benzinga | Jan 5, 2022 06:06AM EST

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $150

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $157 to $150.